Effects of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis.
HIF-1α
HIF-2α
hepatocellular carcinoma
meta-analysis
prognosis
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
08
12
2020
received:
24
07
2020
accepted:
28
12
2020
pubmed:
5
1
2021
medline:
3
11
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
The role of hypoxia-inducible factor-1α (HIF-1α) and hypoxia-inducible factor-2α (HIF-2α) has been implicated in the clinical prognosis of hepatocellular carcinoma (HCC), but the results remain controversial. We aim to investigate the association of HIF-1α and HIF-2α overexpression with the prognosis and clinicopathological features of HCC. A systematic search was conducted in PubMed, Embase, Scopus, Web of Science, and Cochrane Library until June 20, 2020. Meta-analysis was conducted to generate combined HRs with 95% confidence intervals (CI) for overall survival (OS) and disease-free survival (DFS). Odds ratios (ORs) with 95% CI were also derived by fixed or random effect model. Twenty-two studies involving 3238 patients were included. Combined data suggested that overexpression of HIF-1α in HCC was not only correlated with poorer OS [HR = 1.75 (95% CI: 1.53-2.00)] and DFS [HR = 1.64 (95% CI: 1.34-2.00)] but was also positively associated with vascular invasion [OR = 1.83 (95% CI: 1.36-2.48)], tumor size [OR = 1.36 (95% CI: 1.12-1.66)], and tumor number [1.74 (95% CI: 1.34-2.25)]. In contrast, HIF-2α overexpression was not associated with the prognosis and clinicopathological features of HCC. Our data provided compelling evidence of a worse prognosis of HCC in HIF-1α overexpression patients but not HIF-2α overexpression ones.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
The role of hypoxia-inducible factor-1α (HIF-1α) and hypoxia-inducible factor-2α (HIF-2α) has been implicated in the clinical prognosis of hepatocellular carcinoma (HCC), but the results remain controversial. We aim to investigate the association of HIF-1α and HIF-2α overexpression with the prognosis and clinicopathological features of HCC.
METHODS
METHODS
A systematic search was conducted in PubMed, Embase, Scopus, Web of Science, and Cochrane Library until June 20, 2020. Meta-analysis was conducted to generate combined HRs with 95% confidence intervals (CI) for overall survival (OS) and disease-free survival (DFS). Odds ratios (ORs) with 95% CI were also derived by fixed or random effect model.
RESULTS
RESULTS
Twenty-two studies involving 3238 patients were included. Combined data suggested that overexpression of HIF-1α in HCC was not only correlated with poorer OS [HR = 1.75 (95% CI: 1.53-2.00)] and DFS [HR = 1.64 (95% CI: 1.34-2.00)] but was also positively associated with vascular invasion [OR = 1.83 (95% CI: 1.36-2.48)], tumor size [OR = 1.36 (95% CI: 1.12-1.66)], and tumor number [1.74 (95% CI: 1.34-2.25)]. In contrast, HIF-2α overexpression was not associated with the prognosis and clinicopathological features of HCC.
CONCLUSION
CONCLUSIONS
Our data provided compelling evidence of a worse prognosis of HCC in HIF-1α overexpression patients but not HIF-2α overexpression ones.
Substances chimiques
Basic Helix-Loop-Helix Transcription Factors
0
HIF1A protein, human
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
endothelial PAS domain-containing protein 1
1B37H0967P
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1487-1496Subventions
Organisme : National Natural Science Foundation of China
ID : 81874178
Organisme : National Natural Science Foundation of China
ID : 82073200
Organisme : Taishan Scholars Program for Young Expert of Shandong Province
ID : tsqn20161064
Informations de copyright
© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018; 391: 1301-1314.
Li T, Wang SK, Zhou J et al. Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative. Liver Int. 2016; 36: 284-292.
Brown ZJ, Greten TF, Heinrich B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology 2019; 70: 1437-1442.
Li T, Qin LX, Gong X et al. Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma: clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection. Cancer 2013; 119: 126-135.
Dong ZR, Sun D, Yang YF et al. TMPRSS4 drives angiogenesis in hepatocellular carcinoma by promoting HB-EGF expression and proteolytic cleavage. Hepatology 2020; 72: 923-939.
Zundel W, Schindler C, Haas-Kogan D et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000; 14: 391-396.
Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med. 2003; 9: 677-684.
Ma P, Tang WG, Hu JW et al. HSP4 triggers epithelial-mesenchymal transition and promotes motility capacities of hepatocellular carcinoma cells via activating AKT. Liver Int. 2020; 40: 1211-1223.
Haase VH. The VHL tumor suppressor: master regulator of HIF. Curr. Pharm. Des. 2009; 15: 3895-3903.
Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 2001; 13: 167-171.
Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008; 15: 678-685.
Skuli N, Simon MC. HIF-1α versus HIF-2α in endothelial cells and vascular functions: is there a master in angiogenesis regulation? Cell Cycle (Georgetown, Tex) 2009; 8: 3252-3253.
Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI. Hypoxia-inducible factors 1α and 2α are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res. 2003; 13: 493-501.
Kimura S, Kitadai Y, Tanaka S et al. Expression of hypoxia-inducible factor (HIF)-1α is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur. J. Cancer (Oxford, England: 1990) 2004; 40: 1904-1912.
Giatromanolaki A, Koukourakis MI, Sivridis E et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 2001; 85: 881-890.
Ma L, Li G, Zhu H et al. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett. 2014; 355: 96-105.
Zhao D, Zhai B, He C et al. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells. Cell. Signal. 2014; 26: 1030-1039.
Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF, Jing S. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J. Gastroenterol. 2007; 13: 3176-3182.
Moher D, Shamseer L, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015; 4: 1.
Deeks JJ, Dinnes J, D'Amico R et al. Evaluating non-randomised intervention studies. Health Technol. Assess 2003; 7:iii-x: 1-173.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 1998; 17: 2815-2834.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp. Clin. Trials 2015; 45: 139-145.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
Yang SL, Liu LP, Niu L et al. Downregulation and pro-apoptotic effect of hypoxia-inducible factor 2α in hepatocellular carcinoma. Oncotarget 2016; 7: 34571-34581.
Xiao H, Tong R, Cheng S et al. BAG3 and HIF-1α coexpression detected by immunohistochemistry correlated with prognosis in hepatocellular carcinoma after liver transplantation. Biomed. Res. Int. 2014; 2014: 516518.
Zhang L, Huang G, Li X et al. Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor-1α in hepatocellular carcinoma. BMC Cancer 2013; 13: 183.
Cheng W, Cheng Z, Yang Z, Xing D, Zhang M. Upregulation of hypoxia-inducible factor 1α mRNA expression was associated with poor prognosis in patients with hepatocellular carcinoma. Onco. Targets. Ther. 2019; 12: 6285-6296.
Dai CX, Gao Q, Qiu SJ et al. Hypoxia-inducible factor-1α, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009; 9: 418.
Dai X, Pi G, Yang SL, Chen GG, Liu LP, Dong HH. Association of PD-L1 and HIF-1α coexpression with poor prognosis in hepatocellular carcinoma. Transl. Oncol. 2018; 11: 559-566.
Huang GW, Yang LY, Lu WQ. Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J. Gastroenterol. 2005; 11: 1705-1708.
Huang M, Wang L, Chen J et al. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery. Int. J. Oncol. 2016; 48: 2144-2154.
Jiang L, Liu QL, Liang QL, Zhang HJ, Ou WT, Yuan GL. Association of PHD3 and HIF2α gene expression with clinicopathological characteristics in human hepatocellular carcinoma. Oncol. Lett. 2018; 15: 545-551.
Li XP, Yang XY, Biskup E et al. Co-expression of CXCL8 and HIF-1α is associated with metastasis and poor prognosis in hepatocellular carcinoma. Oncotarget 2015; 6: 22880-22889.
Liu L, Zhu XD, Wang WQ et al. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin. Cancer Res. 2010; 16: 2740-2750.
Qian Y, Li Y, Zheng C et al. High methylation levels of histone H3 lysine 9 associated with activation of hypoxia-inducible factor 1alpha (HIF-1α) predict patients' worse prognosis in human hepatocellular carcinomas. Cancer Genet. 2020; 245: 17-26.
Sun HX, Xu Y, Yang XR et al. Hypoxia inducible factor 2α inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/E2F transcription factor 1-dependent apoptotic pathway. Hepatology 2013; 57: 1088-1097.
Wang D, Zhang X, Lu Y, Wang X, Zhu L. Hypoxia inducible factor 1α in hepatocellular carcinoma with cirrhosis: association with prognosis. Pathol. Res. Pract. 2018; 214: 1987-1992.
Wang M, Zhao X, Zhu D et al. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment. J. Exp. Clin. Cancer Res. 2017; 36: 60.
Xia L, Mo P, Huang W et al. The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis 2012; 33: 2250-2259.
Xiang ZL, Zeng ZC, Fan J et al. The expression of HIF-1α in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol. Biol. Rep. 2012; 39: 2021-2029.
Xie H, Song J, Liu K et al. The expression of hypoxia-inducible factor-1α in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein. Dig. Dis. Sci. 2008; 53: 3225-3233.
Yang SL, Liu LP, Jiang JX, Xiong ZF, He QJ, Wu C. The correlation of expression levels of HIF-1α and HIF-2α in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients' clinical outcome. Jpn. J. Clin. Oncol. 2014; 44: 159-167.
Zhang JG, Zhou HM, Zhang X et al. Hypoxic induction of vasculogenic mimicry in hepatocellular carcinoma: role of HIF-1α, RhoA/ROCK and Rac1/PAK signaling. BMC Cancer 2020; 20: 32.
Zou B, Liu X, Zhang B et al. The expression of FAP in hepatocellular carcinoma cells is induced by hypoxia and correlates with poor clinical outcomes. J. Cancer 2018; 9: 3278-3286.
Osman NA, Abd El-Rehim DM, Kamal IM. Defective beclin-1 and elevated hypoxia-inducible factor (HIF)-1α expression are closely linked to tumorigenesis, differentiation, and progression of hepatocellular carcinoma. Tumour Biol. 2015; 36: 4293-4299.
Srivastava S, Thakkar B, Yeoh KG et al. Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma. Virchows Arch. 2015; 466: 541-548.
Wada H, Nagano H, Yamamoto H et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1α. Liver Int. 2006; 26: 414-423.
Cao S, Yang S, Wu C, Wang Y, Jiang J, Lu Z. Protein expression of hypoxia-inducible factor-1α and hepatocellular carcinoma: a systematic review with meta-analysis. Clin. Res. Hepatol. Gastroenterol. 2014; 38: 598-603.
Dong XF, Liu TQ, Zhi XT et al. COX-2/PGE2 axis regulates HIF2α activity to promote hepatocellular carcinoma hypoxic response and reduce the sensitivity of sorafenib treatment. Clin. Cancer Res. 2018; 24: 3204-3216.
Liu Y, Zhang JB, Qin Y et al. PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1α expression and protein stability. Hepatology 2013; 58: 692-705.
Helczynska K, Larsson AM, Holmquist Mengelbier L et al. Hypoxia-inducible factor-2α correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 2008; 68: 9212-9220.
Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL. Relationship of hypoxia-inducible factor (HIF)-1α and HIF-2α expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 2000; 60: 7106-7113.
Kim WY, Perera S, Zhou B et al. HIF2α cooperates with RAS to promote lung tumorigenesis in mice. J. Clin. Invest. 2009; 119: 2160-2170.
El Dika I, Khalil DN, Abou-Alfa GK. Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer 2019; 125: 3312-3319.
Flynn MJ, Sayed AA, Sharma R, Siddique A, Pinato DJ. Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma. Hepatology 2019; 69: 2258-2270.
Shao YY, Liu TH, Hsu C et al. Early α-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int. 2019; 39: 2184-2189.
Messai Y, Gad S, Noman MZ et al. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 α, is regulated by von Hippel-Lindau gene mutation status. Eur. Urol. 2016; 70: 623-632.
Guo R, Li Y, Wang Z et al. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells. Cancer Sci. 2019; 110: 1665-1675.
Ye LY, Chen W, Bai XL et al. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 2016; 76: 818-830.
Zuo HX, Jin Y, Wang Z et al. Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1α and STAT3 (T705) signaling pathways in hepatic cancer. J. Ethnopharmacol. 2020; 257: 112835.
Cui CP, Wong CC, Kai AK et al. SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop. Gut 2017; 66: 2149-2159.
Wilson GK, Brimacombe CL, Rowe IA et al. A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. J. Hepatol. 2012; 56: 803-809.